153 related articles for article (PubMed ID: 20719986)
1. Serological protection induced by Haemophilus influenzae Type B conjugate vaccine in Mexican children: is a booster dose of the vaccine needed?
Rodriguez RS; Mascarenas C; Conde-Glez CJ; Inostroza J; Villanueva S; Velázquez ME; Sánchez-Alemán MA; Echániz G
Clin Vaccine Immunol; 2010 Oct; 17(10):1639-41. PubMed ID: 20719986
[TBL] [Abstract][Full Text] [Related]
2. Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.
Tejedor JC; Merino JM; Moro M; Navarro ML; Espín J; Omeñaca F; García-Sicilia J; Moreno-Pérez D; Ruiz-Contreras J; Centeno F; Barrio F; Cabanillas L; Muro M; Esporrin C; De Torres MJ; Caubet M; Boutriau D; Miller JM; Mesaros N
Pediatr Infect Dis J; 2012 Oct; 31(10):1074-7. PubMed ID: 22828645
[TBL] [Abstract][Full Text] [Related]
3. Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants.
Klein NP; Abu-Elyazeed R; Cornish M; Leonardi ML; Weiner LB; Silas PE; Grogg SE; Varman M; Frenck RW; Cheuvart B; Baine Y; Miller JM; Leyssen M; Mesaros N; Roy-Ghanta S
Vaccine; 2017 Jun; 35(28):3564-3574. PubMed ID: 28536030
[TBL] [Abstract][Full Text] [Related]
4. A randomized, controlled, blinded study of the safety and immunogenicity of Haemophilus influenzae type b conjugate vaccine injected at different intramuscular sites in Chinese infants.
Shi N; Luo F; Li L; Zheng D; Zhang Z; Wang Z; Yang L; Liu Z; Ai X; Bai Y; Lu Q
Hum Vaccin Immunother; 2013 Nov; 9(11):2311-5. PubMed ID: 23842003
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a DTaP-IPV/Hib pentavalent vaccine given as primary and booster vaccinations in healthy infants and toddlers in Japan.
Nakayama T; Vidor E; Tsuzuki D; Nishina S; Sasaki T; Ishii Y; Mizukami H; Tsuge H
J Infect Chemother; 2020 Jul; 26(7):651-659. PubMed ID: 32307307
[TBL] [Abstract][Full Text] [Related]
6. Utilization pattern of Haemophilus influenza type b vaccine in eight provinces of China.
Li Y; Yue C; Wang Y; Zhu X; Martin K; Scherpbier RW; Liu J; Wang Z; Ma Y; Cheng H; Zhang Z; Wang Q; Li H; Xie S; Xiao Q; Wang H; An Z
Hum Vaccin Immunother; 2018 Apr; 14(4):894-899. PubMed ID: 29300680
[TBL] [Abstract][Full Text] [Related]
7. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom.
Heath PT; Booy R; Azzopardi HJ; Slack MP; Bowen-Morris J; Griffiths H; Ramsay ME; Deeks JJ; Moxon ER
JAMA; 2000 Nov; 284(18):2334-40. PubMed ID: 11066183
[TBL] [Abstract][Full Text] [Related]
8. Naturally acquired and conjugate vaccine-induced antibody to Haemophilus influenzae type b (Hib) polysaccharide in Malian children: serological assessment of the Hib immunization program in Mali.
Hutter J; Pasetti MF; Sanogo D; Tapia MD; Sow SO; Levine MM
Am J Trop Med Hyg; 2012 Jun; 86(6):1026-31. PubMed ID: 22665612
[TBL] [Abstract][Full Text] [Related]
9. Haemophilus influenzae serotype b conjugate vaccine failure in twelve countries with established national childhood immunization programmes.
Ladhani S; Heath PT; Slack MP; McIntyre PB; Diez-Domingo J; Campos J; Dagan R; Ramsay ME;
Clin Microbiol Infect; 2010 Jul; 16(7):948-54. PubMed ID: 19889054
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of two doses of catch-up immunization with Haemophilus influenzae type b conjugate vaccine in Indian children living with HIV.
Arya BK; Bhattacharya SD; Sutcliffe CG; Saha MK; Bhattacharyya S; Niyogi SK; Moss WJ; Panda S; Das RS; Mallick M; Mandal S
Vaccine; 2016 Apr; 34(19):2267-74. PubMed ID: 26988256
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine.
Borrow R; Andrews N; Findlow H; Waight P; Southern J; Crowley-Luke A; Stapley L; England A; Findlow J; Miller E
Clin Vaccine Immunol; 2010 Jan; 17(1):154-9. PubMed ID: 19906895
[TBL] [Abstract][Full Text] [Related]
12. Impaired haemophilus influenzae type b transplacental antibody transmission and declining antibody avidity through the first year of life represent potential vulnerabilities for HIV-exposed but -uninfected infants.
Gaensbauer JT; Rakhola JT; Onyango-Makumbi C; Mubiru M; Westcott JE; Krebs NF; Asturias EJ; Fowler MG; McFarland E; Janoff EN
Clin Vaccine Immunol; 2014 Dec; 21(12):1661-7. PubMed ID: 25298109
[TBL] [Abstract][Full Text] [Related]
13. Circulating innate and adaptive immunity against anti-Haemophilus influenzae type b.
Zarei AE; Linjawi MH; Redwan EM
Hum Antibodies; 2019; 27(3):201-212. PubMed ID: 30958343
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.
Hu JL; Tao H; Li JX; Dai WM; Song B; Sun JF; Liu P; Tang J; Liu WY; Wang SY; Zhu FC
Hum Vaccin Immunother; 2015; 11(5):1120-8. PubMed ID: 25833163
[TBL] [Abstract][Full Text] [Related]
15. A nationwide population-based surveillance of invasive Haemophilus influenzae diseases in children after the introduction of the Haemophilus influenzae type b vaccine in Japan.
Suga S; Ishiwada N; Sasaki Y; Akeda H; Nishi J; Okada K; Fujieda M; Oda M; Asada K; Nakano T; Saitoh A; Hosoya M; Togashi T; Matsuoka M; Kimura K; Shibayama K
Vaccine; 2018 Sep; 36(38):5678-5684. PubMed ID: 30122645
[TBL] [Abstract][Full Text] [Related]
16. The seroepidemiology of Haemophilus influenzae type b prior to introduction of an immunization programme in Kathmandu, Nepal.
Marshall AS; Barker CI; Pulickal AS; Kibwana E; Gautam SC; Clutterbuck EA; Thorson SM; Shrestha S; Adhikari N; Pollard AJ; Kelly DF
PLoS One; 2014; 9(1):e85055. PubMed ID: 24465475
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of an indigenously developed Haemophilus influenzae type b conjugate vaccine through various phases of clinical trials.
Sharma HJ; Multani AS; Dutta AK; Joshi SM; Malik S; Bhardwaj S; Chakravarty A; Namjoshi GS; Parekh S; Verma V
Hum Vaccin; 2009 Jul; 5(7):483-7. PubMed ID: 19395868
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy.
Southern J; McVernon J; Gelb D; Andrews N; Morris R; Crowley-Luke A; Goldblatt D; Miller E
Clin Vaccine Immunol; 2007 Oct; 14(10):1328-33. PubMed ID: 17699835
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of LBVH0101, a new Haemophilus influenzae type b tetanus toxoid conjugate vaccine, compared with Hiberix™ in Korean infants and children: a randomized trial.
Kim KH; Kim YK; Kim NH; Chang SH; Lee J; Park EA; Park SE; Eun BW; Lee H; Lee HJ
Vaccine; 2012 Feb; 30(10):1886-94. PubMed ID: 22245607
[TBL] [Abstract][Full Text] [Related]
20. Safety and antibody persistence following Haemophilus influenzae type b conjugate or pneumococcal polysaccharide vaccines given before pregnancy in women of childbearing age and their infants.
Santosham M; Englund JA; McInnes P; Croll J; Thompson CM; Croll L; Glezen WP; Siber GR
Pediatr Infect Dis J; 2001 Oct; 20(10):931-40. PubMed ID: 11642626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
